Menü Kapat

Urotoxicity and safety data of low-dose intravenous cyclophosphamide therapy for rheumatic diseases: A Single-Center retrospective cohort study

Orjinal Article

Urotoxicity and safety data of low-dose intravenous cyclophosphamide therapy or rheumatic diseases: A Single-Center retrospective cohort study

Receiving Date: 07 March 2022

Accept Date: 21 May 2022

Available Online: 20.06.2022

doi: 10.5455/medscience.2022.03.055

Medicine Science 2022;11(3):1003-6

Conflict of interests: The authors declare that there is no conflict of interest in the study.
Financial Disclosure: The authors declare that they have received no financial support for the study.
Ethical approval: The study was approved by the X University Institutional Review Board and Ethics Committee (Project no: KA21/74) and supported by the Başkent University Research Fund.

Table 1. Patients' demographic, clinical and laboratory data

 3,488 total views,  1 views today

Tufan MA, Tekkarismaz N, Dalgic GS, Yucel AE. Urotoxicity and safety data of low-dose intravenous cyclophosphamide therapy for rheumatic diseases: A Single-Center retrospective cohort study
. Med Science. 2022;11(3):1003-6.

⇓ PlumX Meter

Corresponding Author:Muge Aydin Tufan, Baskent University Faculty of Medicine, Department of Rheumatology, Adana, Turkey.
E-mail: mugeaydin@yahoo.com